Clinical Trial Update: IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial is evaluating IPG7236 in combination with toripalimab for advanced solid tumors. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• IPG7236
• Toripalimab (Toripalimab)

Snippet

Sponsor: Nanjing Immunophage Biotech Co., Ltd | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING